Literature DB >> 25442930

Public-private partnership: a new engine for translational research in neurosciences.

Declan G M Murphy1, Michel Goldman2, Eva Loth3, Will Spooren4.   

Abstract

We have made little recent progress developing effective new treatments for neuropsychiatric and neurodevelopmental disorders. Novel molecular mechanisms have been identified, but have not translated into the clinic. We suggest an alternative: combinations of treatments targeting different aspects of final common pathways in biologically defined clinical subgroups. This will require integrated translational neuroscience and international public-private partnerships.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 25442930     DOI: 10.1016/j.neuron.2014.10.006

Source DB:  PubMed          Journal:  Neuron        ISSN: 0896-6273            Impact factor:   17.173


  5 in total

1.  Preclinical research strategies for newly approved drugs as reflected in early publication patterns.

Authors:  Ursula Köster; Ingo Nolte; Martin C Michel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2015-11-26       Impact factor: 3.000

2.  Expectations and satisfaction of academic investigators in nonclinical collaboration with the pharmaceutical industry.

Authors:  Marjan Amiri; Martin C Michel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2015-02-28       Impact factor: 3.000

3.  The price of progress: Funding and financing Alzheimer's disease drug development.

Authors:  Jeffrey Cummings; Carl Reiber; Parvesh Kumar
Journal:  Alzheimers Dement (N Y)       Date:  2018-06-13

Review 4.  The Innovative Medicines Initiative -10 Years of Public-Private Collaboration.

Authors:  Hugh Laverty; Pierre Meulien
Journal:  Front Med (Lausanne)       Date:  2019-12-03

5.  Who funds Alzheimer's disease drug development?

Authors:  Jeffrey Cummings; Justin Bauzon; Garam Lee
Journal:  Alzheimers Dement (N Y)       Date:  2021-05-25
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.